Researchers at Colorado State University have determined how to use artificial intelligence to modify antibodies so they act ...

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its ...

Antibody drugs such as monoclonal antibodies (mAb), bispecific antibodies, antibody-drug conjugates (ADCs), and nanobodies garnered increased interest in research and development circles. Sino ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. In April 2021, the FDA approved the 100th monoclonal ...

Monoclonal antibodies (mAbs) aid the body against autoimmune diseases and cancer, among other things. Patients have to pick ...

For therapies based on monoclonal antibodies (mAbs), bioprocessors continually search for ways to improve the development process. Machine learning (ML) offers one useful tool. As Mariano Nicolas Cruz ...

This study presents a comprehensive approach for assessing multiple quality attributes of antibody-oligonucleotide conjugates ...

Given the multifaceted nature of ADCs, developers should have an integrated analytical toolkit. Three complementary approaches dominate the current landscape: Ligand Binding Assays (LBA): Ideal for ...

Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro ...

A lack of targeting specificity has been a long-running problem for cytotoxic anticancer agents, with excess side effects limiting their effectiveness. Scientists have turned to antibodies, and their ...

iBio (IBIO) in collaboration with AstralBio announced the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity ...